Clinical Trials Browser

Terminated × IT-101 × Clear all

NCT03531827 2022-07-12

Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment

Phase 2 Terminated

4 enrolled 12 charts

Prostatic Neoplasms

NCT02010567 2020-11-03

Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer

Phase 1/2 Terminated

32 enrolled 18 charts

Gastrointestinal

Rectal Neoplasms, Colorectal Neoplasms

NCT01803269 2020-06-26

Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating Patients With Recurrent Small Cell Lung Cancer

Phase 2 Terminated

29 enrolled 14 charts

Small Cell Lung Carcinoma

NCT02389985 2020-05-28

A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Phase 1/2 Terminated

Ovarian Neoplasms

NCT02648711 2020-05-28

Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors

Phase 1 Terminated

Other solid neoplasm

Solid Tumors